XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Revenue Recognition (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Revenue Recognition |
Schedule of disaggregation of revenue | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Collaborative revenue | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (KORSUVA injection profit sharing) | ​ | $ | 788 | ​ | $ | 2,750
Total collaborative revenue | ​ | $ | 788 | ​ | $ | 2,750
Commercial supply revenue | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor* (KORSUVA injection) | ​ | $ | 640 | ​ | $ | 3,191
Total commercial supply revenue | ​ | $ | 640 | ​ | $ | 3,191
Royalty revenue | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (Kapruvia ex-U.S.) | ​ | $ | — | ​ | $ | 125
Total royalty revenue | ​ | $ | — | ​ | $ | 125
Clinical compound revenue | ​ | ​ | ​ | ​ | ​ | ​
Maruishi | ​ | $ | 84 | ​ | $ | 99
Total clinical compound revenue | ​ | $ | 84 | ​ | $ | 99
Other revenue (non-cash) | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (Kapruvia ex-U.S.) | ​ | $ | 290 | ​ | $ | —
Maruishi | ​ | ​ | 333 | ​ | ​ | —
Total other revenue | ​ | $ | 623 | ​ | $ | —
​

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration